Confo Therapeutics

30 articles about Confo Therapeutics

• Confo Therapeutics Reports Grant of Two Key Patents for ConfoBodies™

  12/2/2019

  Confo Therapeutics, a pioneering biopharma company, announces that it has been granted two key ConfoBodyTM patents derived from the patent estate known as the “Steyaert patents”.

• Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

  7/3/2019

  Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH announce a drug discovery collaboration on an undisclosed G-protein coupled receptor.

• Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication

  6/20/2019

  Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO).

• Confo Therapeutics Raises €30 Million in Series A Financing

  5/7/2019

  Round led by BioGeneration Ventures and co-led by Wellington Partners, with investments by Fund+, Perceptive Advisors and existing investors

• 

  BioSpace Movers and Shakers: March 1

  3/1/2019

  Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more.

• Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology

  1/3/2019

  Confo Therapeutics today announces that it has entered into an agreement with VIB, a life sciences research institute in Flanders, Belgium, for an exclusive, worldwide license to VIB’s ‘Megabody’ technology.

• 

  BioSpace Movers and Shakers for Dec. 10

  12/10/2018

  Biotech and pharma companies strengthen their leadership teams with these appointments. Who made power moves in the industry this past week?

• Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property

  12/6/2018

  Confo Therapeutics today announces the appointment of Frank Landolt as its Chief Counsel Legal & IP, effective from 1 January 2019.

• 

  Belgium Biotech Inks Drug Discovery Pact With Roche

  12/19/2017

  Confo Therapeutics announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed GPCR for the treatment of neurological and developmental disorders.

• Confo Therapeutics Secures €6.7 Million In First Financing Round

  2/2/2016